Düsseldorf, Germany

Lars Linden

USPTO Granted Patents = 6 

 

 

Average Co-Inventor Count = 5.5

ph-index = 2

Forward Citations = 42(Granted Patents)


Location History:

  • Düsseldorf, DE (2015 - 2017)
  • Gevelsberg, DE (2021 - 2022)

Company Filing History:


Years Active: 2015-2022

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):

Title: Lars Linden: Innovator in Radio-pharmaceuticals and Monoclonal Antibodies

Introduction

Lars Linden is a notable inventor based in Düsseldorf, Germany. He has made significant contributions to the fields of radio-pharmaceuticals and monoclonal antibodies. With a total of 6 patents to his name, his work has the potential to impact medical treatments significantly.

Latest Patents

Linden's latest patents include innovative methods for creating tissue-targeting thorium complexes. This invention outlines a method that involves forming an octadentate chelator with specific moieties and coupling it to a tissue-targeting moiety that targets HER2. Additionally, he has developed a method for treating neoplastic or hyperplastic diseases using these thorium complexes. Another significant patent involves optimized humanized monoclonal antibodies that selectively bind to activated protein C, providing new avenues for treatment without affecting unactivated protein C.

Career Highlights

Throughout his career, Lars Linden has worked with prominent companies such as Bayer Intellectual Property GmbH and Seattle Genetics, Inc. His experience in these organizations has allowed him to refine his expertise in the development of innovative medical solutions.

Collaborations

Linden has collaborated with notable professionals in his field, including Andreas Wilmen and Christoph Freiberg. These partnerships have contributed to the advancement of his research and inventions.

Conclusion

Lars Linden's contributions to the fields of radio-pharmaceuticals and monoclonal antibodies demonstrate his commitment to innovation in medical science. His patents reflect a deep understanding of complex biological interactions and a dedication to improving treatment options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…